Multimodal imaging characteristics and clinicopathological profile of primary gastrointestinal mucosal melanoma: a descriptive retrospective case series
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background Gastrointestinal mucosal melanoma is a rare, aggressive malignancy for which diagnosis and management remain challenging. This single-center case series describes its clinicopathological features, multimodal imaging findings, treatment patterns, and outcomes. Methods We retrospectively reviewed 15 patients with histologically confirmed gastrointestinal mucosal melanoma treated between 2017 and 2023. Clinical characteristics, CT, MRI, PET-CT findings, immunohistochemical profiles, treatment, and survival were summarized. Imaging was considered supportive for lesion characterization and staging rather than diagnostic. Overall survival was estimated using Kaplan–Meier analysis; treatment comparisons were exploratory because of the small, non-randomized cohort. Results The cohort included 10 men and 5 women, with a median age of 66 years (range, 49–82); 73.3% of tumors were colorectal/anorectal and 26.7% gastric. Gastrointestinal bleeding (80.0%), abdominal pain (66.7%), and weight loss (53.3%) were common. CT showed unenhanced hyperattenuation in 66.7% and moderate-to-marked enhancement in 86.7%. Among six MRI-evaluated patients, T1 hyperintensity occurred in 83.3% and T2 hypointensity in 66.7%. HMB45, S100, Melan-A, and SOX10 were positive in 80.0% (12/15), 92.9% (13/14), 92.9% (13/14), and 100% (6/6) of tested cases, respectively. Median overall survival was 11 months. In an exploratory analysis, median survival was 20 months with surgery plus immunotherapy versus 7 months with surgery alone (log-rank p=0.003). Conclusions Gastrointestinal mucosal melanoma shows heterogeneous pathological and imaging findings. Histopathology and immunohistochemistry remain central to diagnosis, whereas multimodal imaging is most useful for disease assessment. Larger multicenter studies with appropriate comparators are needed.
Source: Frontiers in Oncology
Institution: Shengli Oilfield Central Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7236085869
